Rosenblum Silverman Sutton’s Celgene Corp CELG Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2019
Q1
Sell
-6,069
Closed -$660K 68
2018
Q4
$660K Sell
6,069
-60,112
-91% -$4.44M 0.3% 52
2018
Q3
$5.92M Sell
66,181
-215
-0.3% -$19K 1.96% 19
2018
Q2
$5.27M Sell
66,396
-1,600
-2% -$133K 1.83% 20
2018
Q1
$6.07M Sell
67,996
-915
-1% -$87.8K 2.16% 15
2017
Q4
$7.19M Buy
68,911
+1,430
+2% +$161K 2.58% 13
2017
Q3
$9.84M Buy
67,481
+2,975
+5% +$405K 3.74% 6
2017
Q2
$8.38M Buy
64,506
+375
+0.6% +$45.9K 3.35% 7
2017
Q1
$7.98M Sell
64,131
-554
-0.9% -$66.3K 3.38% 6
2016
Q4
$7.49M Sell
64,685
-3,400
-5% -$379K 3.54% 5
2016
Q3
$7.12M Sell
68,085
-1,235
-2% -$134K 3.26% 7
2016
Q2
$6.84M Buy
+69,320
New +$7.17M 3.28% 5
2015
Q4
$8.5M Sell
71,000
-3,280
-4% -$379K 3.88% 6
2015
Q3
$8.04M Sell
74,280
-2,975
-4% -$369K 3.83% 5
2015
Q2
$8.94M Buy
+77,255
New +$8.83M 3.58% 6
2014
Q4
$8.96M Sell
80,110
-975
-1% -$103K 3.86% 5
2014
Q3
$7.68M Buy
81,085
+545
+0.7% +$49.2K 3.46% 8
2014
Q2
$6.92M Buy
80,540
+2,610
+3% +$198K 3.23% 8
2014
Q1
$5.44M Buy
77,930
+880
+1% +$69.7K 2.58% 12
2013
Q4
$6.51M Sell
77,050
-1,010
-1% -$79.9K 3.08% 7
2013
Q3
$6.02M Buy
+78,060
New +$5.47M 3.22% 5

Other funds holding CELG

Rosenblum Silverman Sutton's CELG Position: Q1 2019 in Review

Rosenblum Silverman Sutton sold out of Celgene Corp (CELG) in Q1 2019, closing a stake of 6,069 shares — an estimated $660K sold.

Rosenblum Silverman Sutton first reported a position in CELG in Q3 2013 and held it in 20 quarters. The position peaked at $9.84M in Q3 2017. 1,389 funds tracked by Wall St. Rank hold CELG as of Q1 2019.

  • Rosenblum Silverman Sutton reported no remaining Celgene Corp position as of Q1 2019 after selling out during the quarter.
  • Rosenblum Silverman Sutton sold 6,069 Celgene Corp shares in Q1 2019, an estimated $660K.
  • Rosenblum Silverman Sutton first reported a position in Celgene Corp in Q3 2013 and held it in 20 quarters.
  • Rosenblum Silverman Sutton's Celgene Corp position peaked at $9.84M in Q3 2017.
  • 1,389 funds tracked by Wall St. Rank held Celgene Corp as of Q1 2019.

Based on Rosenblum Silverman Sutton's 13F filing for Q1 2019, filed 25 Apr 2019.